Skip to main content

Table 5 Supporting agents used in treatment

From: COVID-19 pandemic crisis—a complete outline of SARS-CoV-2

Antiviral agents Supporting agents Others
• Baloxavir
• Chloroquine phosphate
• Favipiravir
• HIV protease inhibitors
• Hydroxychloroquine
• Neuraminidase inhibitor
• Remdesivir
• Umifenovir
• Anakinra
• Azithromycin
• Baricitinib (Olumiant®)
• Colchicine
• Corticosteroids (general)
• COVID-19
• Convalescent plasma
• Epoprostenol (inhaled)
• Methylprednisolone (DEPO-Medrol®, SOLU-Medrol®)
• Nitric oxide (inhaled)
• Ruxolitinib (Jakafi®)
• Sarilumab (Kefzara®)
• Siltuximab (Sylvant®)
• Sirolimus (Rapamune®)
• Tocilizumab (Actemra®)
• ACE inhibitors, angiotensin II receptor blockers (ARBs)
• Anticoagulants (low molecular weight heparin [LMWH], unfractionated heparin [UFH])
• Famotidine
• HMG-CoA reductase inhibitors (statins)
• Immune globulin (IGIV, IVIG, γ-globulin)
• Ivermectin
• Nebulized drugs
• Niclosamide
• Nitazoxanide
• Nonsteroidal anti-inflammatory agents (NSAIDs)
• Tissue plasminogen activator (t-PA; alteplase)
  1. The repurposing of available therapeutic drugs is being used as supporting agents in the treatment of COVID-19; however, the efficacy of these treatments should be verified by using designed clinical trials